Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma

NCT01342757 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

12

Enrollment

NIH

Sponsor class

Conditions

Adult Glioblastoma
Depression
Recurrent Adult Brain Tumor

Interventions

DRUG: vorinostat
DRUG: temozolomide
PROCEDURE: magnetic resonance spectroscopic imaging
OTHER: survey administration

Sponsor

National Cancer Institute (NCI)